A Patent Decision on Crispr Gene Editing Favors MIT

THE FIGHT OVER who owns the most promising technique for editing genes—cutting and pasting the stuff of life to cure disease and advance scientific knowledge—has been a rough one. A team on the West Coast, at UC Berkeley, filed patents on the method, Crispr-Cas9; a team on the East Coast, based at MIT and the Broad Institute, filed their own patents in 2014 after Berkeley’s but got them granted first. The Berkeley group contended that this constituted “interference,” and that Berkeley deserved the patent.